Patents by Inventor Xiaoyan QIU

Xiaoyan QIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240160306
    Abstract: A display panel, including an active area and a peripheral area, which is located outside of the active area, wherein the active area comprises a base substrate, and a display structure layer and a touch structure layer sequentially arranged on the base substrate; the peripheral area includes an isolation dam, a first ground trace and a second ground trace arranged on the base substrate; and the first ground trace is located at a side of the isolation dam close to the active area, and the second ground trace is located at a side of the isolation dam away from the active area.
    Type: Application
    Filed: January 9, 2023
    Publication date: May 16, 2024
    Inventors: Chang LUO, Xiping LI, Hongwei MA, Ming HU, Wei HE, Youngyik KO, Haijun QIU, Yi ZHANG, Taofeng XIE, Tianci CHEN, Qun MA, Xinghua LI, Ping WEN, Yang ZHOU, Yuanqi ZHANG, Xiaoyan YANG, Shun ZHANG, Pandeng TANG, Yang ZENG, Tong ZHANG, Xiaofei HOU, Zhidong WANG, Haoyuan FAN, Jinhwan HWANG
  • Publication number: 20200369785
    Abstract: IgG epitope and applications thereof as a target are provided. The IgG epitope is the CH1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin ?4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.
    Type: Application
    Filed: August 8, 2018
    Publication date: November 26, 2020
    Applicant: Beijing SIG Biopharmaceutical Technology Co., Ltd.
    Inventors: Xiaoyan QIU, Jingshu TANG, Zhi YANG, Chong WANG, Jingxuan ZHANG, Hua ZHU, Zihan GENG, Yang LIU, Wenhua JIANG, Jing HUANG